- Home
- SOL vs ALLK Comparison
SOL vs ALLK Comparison
Compare SOL & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- ALLK
- Stock Information
- Founded
- SOL 2005
- ALLK 2012
- Country
- SOL United States
- ALLK United States
- Employees
- SOL N/A
- ALLK N/A
- Industry
- SOL Semiconductors
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- SOL Technology
- ALLK Health Care
- Exchange
- SOL Nasdaq
- ALLK Nasdaq
- Market Cap
- SOL 104.0M
- ALLK 101.0M
- IPO Year
- SOL 2008
- ALLK 2018
- Fundamental
- Price
- SOL $2.01
- ALLK $1.04
- Analyst Decision
- SOL Buy
- ALLK Hold
- Analyst Count
- SOL 3
- ALLK 4
- Target Price
- SOL $3.83
- ALLK $1.67
- AVG Volume (30 Days)
- SOL 277.5K
- ALLK 838.5K
- Earning Date
- SOL 11-14-2024
- ALLK 03-13-2025
- Dividend Yield
- SOL N/A
- ALLK N/A
- EPS Growth
- SOL N/A
- ALLK N/A
- EPS
- SOL N/A
- ALLK N/A
- Revenue
- SOL $102,489,000.00
- ALLK N/A
- Revenue This Year
- SOL N/A
- ALLK N/A
- Revenue Next Year
- SOL $47.66
- ALLK N/A
- P/E Ratio
- SOL N/A
- ALLK N/A
- Revenue Growth
- SOL 25.98
- ALLK N/A
- 52 Week Low
- SOL $1.41
- ALLK $0.54
- 52 Week High
- SOL $3.00
- ALLK $1.69
- Technical
- Relative Strength Index (RSI)
- SOL 50.68
- ALLK 53.75
- Support Level
- SOL $1.86
- ALLK $0.81
- Resistance Level
- SOL $2.17
- ALLK $1.00
- Average True Range (ATR)
- SOL 0.13
- ALLK 0.14
- MACD
- SOL -0.00
- ALLK -0.00
- Stochastic Oscillator
- SOL 38.64
- ALLK 61.22
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.